期刊文献+

儿童肢体骨肉瘤患者的多中心回顾性临床预后分析 被引量:4

A multi-center retrospective analysis of clinical prognosis in children with extremity osteosarcoma
原文传递
导出
摘要 目的探讨影响儿童肢体骨肉瘤患儿(≤14岁)临床预后的相关因素。方法回顾性分析2000年6月至2017年10月国内7家骨肿瘤治疗中心收治的14岁以下肢体骨肉瘤患儿的病历资料,记录其一般资料、外科分期、术前有无穿刺活检、化疗方案、化疗次数、手术方式、复发转移及生存预后情况,应用Kaplan-Meier法描绘生存曲线并计算生存率,应用Log-rank检验进行单因素生存预后分析,应用Cox回归模型进行多因素的生存预后分析。结果肢体骨肉瘤患儿共147例,男73例,女74例。肢体骨肉瘤患儿的3、5年总生存率分别为65%、53%,中位总生存时间103个月(95%CI:92.8~128.5),3、5年的无瘤生存率分别为46%、38%,中位无瘤生存时间为33个月(95%CI:71.9~104.3)。膝关节周围:123例,膝关节以外:24例。Enneking外科分期:Ⅱ期139例,Ⅲ期8例。其中应用保肢术128例,截肢术19例。规范化疗组78例,非规范化疗组69例,规范化疗组与非规范化疗组5年总生存率分别为62%、43.8%;5年无瘤生存率分别为50.2%、31.6%。无复发转移的有75例,单纯复发13例,单纯转移41例,多发转移(包括复发伴转移)18例,其5年总生存率分别为88%、51.3%、21.4%、0。单因素分析结果显示:规范化疗、Enneking外科分期、术后辅助化疗次数和复发转移是影响肢体骨肉瘤患儿生存预后的相关因素(P<0.05);而性别、部位、手术方式及化疗方案中是否应用甲氨蝶呤(MTX)不是影响患儿生存预后的相关因素(P>0.05)。Cox回归多因素分析结果显示:规范化疗和复发转移是影响肢体骨肉瘤患儿生存预后的独立因素。结论规范的进行辅助化疗、有效的控制复发和转移可以提高肢体骨肉瘤患儿(≤14岁)的生存率,改善患儿的预后,化疗的不规范及复发转移严重影响患儿的预后。 Objective To explore the relevant influencing factors of clinical prognosis of children aged≤14 years with extremity osteosarcoma.Methods A retrospective analysis was performed for medical records of children aged≤14 years with extremity osteosarcoma admitted into seven bone cancer treatment centers in China from June 2000 to October 2017.The general data,surgical stage,preoperative biopsy,regimen/number of chemotherapy,surgical approach,recurrence,metastasis and survival prognosis were recorded.A Kaplan-Meier method was employed for plotting survival curve and calculating survival rate.A log-rank analysis was performed for determining the prognostic factors related to survival rate.And Cox model multivariate analysis was employed for identifying independent prognostic factors.Results There were 73 boys and 74 girls.They had a 3-and 5-year overall survival rates of 65%and 53%,with a median overall survival of 103 months(95%CI:92.8 to 128.5),a 3/5-year disease-free survival rates of 46%and 38%and a median disease-free survival of 33 months(95%CI:71.9 to 104.3).They were around knee joint(n=123)and outside knee joint(n=24).The Enneking surgical stage wasⅡ(n=139)andⅢ(n=8).There were extremity salvage(n=128)and amputation(n=19).The chemotherapy was standard(n=78)and non-standard(n=69).The 5-year overall survival rates of standard and non-standard chemotherapy groups were 62%and 43.8%respectively.The 5-year disease-free survival rates were 50.2%and 31.6%respectively.There were no recurrence or metastasis(n=75),simple recurrence(n=13),simple metastasis(n=41)and multiple metastases(n=18,including recurrence&metastasis).The 5-year overall survival rate was 88%,51.3%,21.4%and 0 respectively.Univariate analysis showed that standard chemotherapy,Enneking surgical stage,frequency of postoperative adjuvant chemotherapy,recurrence and metastasis were the relevant influencing factors of survival and prognosis of children with extremity osteosarcoma(P<0.05).However,gender,location,surgical approach and whether or not using methotrexate(MTX)in chemotherapy regimen were not the relevant influencing factors of survival and prognosis(P>0.05).Cox regression multivariate analysis showed that standard chemotherapy,recurrence and metastasis were independent influencing factors of survival and prognosis of children with extremity osteosarcoma(P<0.05).Conclusions Standard neoadjuvant chemotherapy and effective control of recurrence and metastasis can improve the survival rate and prognosis of children with extremity osteosarcoma.Non-standard chemotherapy.Recurrence and metastasis adversely affect the prognosis of patients.
作者 宋帅 吴苏稼 王臻 张伟滨 胡永成 张国川 姚阳 王文剑 于秀淳 Song Shuai;Wu Sujia;Wang Zhen;Zhang Weibin;Hu Yongcheng;Zhang Guochuan;Yao Yang;Wang Wenjian;Yu Xiuchun(Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Department of Orthopedics,No.960 Hospital of PLA,Jinan 250000,China;Department of Orthopedics,General Hospital of PLA Eastern Theater,Nanjing 210000,China;Department of Orthopedic Oncology,Xijing Hospital,Air Force Military Medical University,Xi'an 130022,China;Department of Orthopedics,Shanghai Ruijin Hospital,Shanghai 200025,China;Department of Orthopedic Oncology,Tianjin Hospital,Tianjin 300000,China;Department of Orthopedic Oncology,Third Affiliated Hospital,Hebei Medical University,Shijiazhuang 050051,China;Department of Oncology,Shanghai Sixth People's Hospital,Shanghai 200233,China)
出处 《中华小儿外科杂志》 CSCD 北大核心 2020年第2期133-139,共7页 Chinese Journal of Pediatric Surgery
关键词 骨肉瘤 肢体 儿童 多中心研究 预后 Osteosarcoma Limb Child Multicenter study Prognosis
  • 相关文献

参考文献6

二级参考文献46

  • 1黄钢,刘剑帆,徐学政,李林勤.新辅助化疗治疗儿童骨肉瘤[J].医学临床研究,2007,24(3):423-425. 被引量:4
  • 2Eyre R, Feltbower RG, Muhwandarikwa E, et al. Epidemiology of bone tumours in children and young adults. Pediatr Blood Can- cer, 2009, 53(6): 941-952.
  • 3Eyre R, Feltbower RG, Mubwandarikwa E, et al. Incidence and survival of childhood bone cancer in northern England and the West Midlands, 1981-2002. Br J Cancer, 2009, 100(1): 188-193.
  • 4Mirabello L, Troisi R J, Savage SA. I International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer, 2009, 125(1): 229-234.
  • 5Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in higll-grade osteosarcoma of the extremities or trunk: an analy- sis of 1,702 patients treated on neoadjuvant cooperative osteosar- coma study group protocols. J Clin Oncol, 2002, 20(3): 776-790.
  • 6Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experi- ence at Rizzoli Institute, Italy. Eur J Cancer, 2005, 41(18): 2836- 2845.
  • 7Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemothera- py with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol, 2005, 23(34): 8845-8852.
  • 8Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS- 82) with salvage chemotherapy based on histological tumor re- sponse. J Clin Oncol, 1988, 6(2): 329-337.
  • 9Kager L, Zoubek A, Ptschger U, et al. Primary metastatic os- teosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol, 2003, 21(10): 2011-2018.
  • 10Carry CP, Dickinson IC, Watts MC, et al. Impairment and dis- ability following limb salvage procedures for bone sarcoma.Knee, 2009, 16(5): 405-408.

共引文献63

同被引文献27

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部